Efficacy and safety of tadalafil 5 mg administered once daily in Korean men with erectile dysfunction: A prospective, multicenter study

Korean Journal of Urology

Volumn 51, Issue 9, 2010, Pages 647-652

  Kang, Dong Hyuk ^a   Lee, Joo Yong ^a   Park, Sung Yul ^a   Moon, Hong Sang ^a   Jeong, Tae Yoong ^b   Yoo, Tag Keun ^c   Choi, Hong Yong ^a   Park, Hae Young ^a   Lee, Tchun Yong ^a   Lee, Seung Wook ^c  

^a Hanyang University College of Medicine   (South Korea)

^b Kwandong University College of Medicine   (South Korea)

^c Eulji General Hospital   (South Korea)

Author keywords

Erectile dysfunction; Safety; Tadalafil; Treatment outcome

Indexed keywords

TADALAFIL;

ADULT; ARTICLE; CLINICAL TRIAL; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; MULTICENTER STUDY; SEXUAL INTERCOURSE; SIDE EFFECT; TREATMENT OUTCOME;

EID: 77956925500     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2010.51.9.647     Document Type: Article

References (28)

1. Lue TF. Erectile dysfunction. N Engl J Med 2000;342:1802-13.
2. McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000;12(Suppl 4):S6-11.
3. Kim JJ, Moon DG. Past, present and future of PDE5 inhibitor. Korean J Androl 2008;26:49-60.
4. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002;168:1332-6.
5. Masson P, Lambert SM, Brown M, Shabsigh R. PDE-5 inhibitors: current status and future trends. Urol Clin North Am 2005;32:511-25.
6. Ahn TY, Lee DS, Kang W, Hong JH, Kim YS. Validation of an abridged Korean version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Korean J Urol 2001;42:535-40.
7. Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010;57:804-14.
8. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med 2007;120:151-7.
9. Rubio-Aurioles E, Casabe A, Torres LO, Quinzanos L, Glina S, Filimon I, et al. Efficacy and safety of tadalafil in the treatment of Latin American men with erectile dysfunction: results of integrated analyses. J Sex Med 2008;5:1965-76.
10. Kim HW, Park WJ, Choi YS, Cho SY. The correlation between erectile dysfunction and the severity of coronary artery involvement in patients with coronary artery disease. Korean J Urol 2007;48:94-102.
11. Kam SC, Choi SM, Jeh SU, Lee SH, Hwa JS, Jung KH, et al. Efficacy and safety of a herbal formula that mainly consists of cornus officinalis for erectile dysfunction: a double-blind, placebo-controlled study. Korean J Urol 2007;48:741-7.
12. Lee U, Lee M, Kim SY, Ji YH, Hong JH, Ahn TY. Clinical efficacy and safety of sildenafil in the men with erectile dysfunction in Korea. Korean J Urol 2001;42:435-40.
13. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998;338:1397-404.
14. Yoo C, Park J, Kim W, Hong B, Hong J, Ahn TY. Comparison of the efficacy, safety and patient preference of the phosphodiesterase type 5 inhibitors for the patients with erectile dysfunction Korean J Urol 2007;48:219-25.
15. Ormrod D, Easthope SE, Figgitt DP. Vardenafil. Drugs Aging 2002;19:217-27.
16. Eardley I, Cartledge J. Tadalafil (Cialis) for men with erectile dysfunction. Int J Clin Pract 2002;56:300-4.
17. Kuan J, Brock G. Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction. Expert Opin Investig Drugs 2002;11:1605-13.
18. Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J, et al. EAU Guidelines on erectile dysfunction: an update. Eur Urol 2006;49:806-15.
19. Althof SE, Eid JF, Talley DR, Brock GB, Dunn ME, Tomlin ME, et al. Through the eyes of women: the partners' perspective on tadalafil. Urology 2006;68:631-5.
20. Rubio-Aurioles E, Kim ED, Rosen RC, Porst H, Burns P, Zeigler H, et al. Impact on erectile function and sexual quality of life of couples: a double-blind, randomized, placebo-controlled trial of tadalafil taken once daily. J Sex Med 2009;6:1314-23.
21. Carson CC, Rajfer J, Eardley I, Carrier S, Denne JS, Walker DJ, et al. The efficacy and safety of tadalafil: an update. BJU Int 2004;93:1276-81.
22. Eardley I, Dean J, Barnes T, Kirby M, Glasser D, Solanki J. The sexual habits of British men and women over 40 years old. BJU Int 2004;93:563-7.
23. Fisher WA, Rosen RC, Eardley I, Sand M, Goldstein I. Sexual experience of female partners of men with erectile dysfunction: the female experience of men's attitudes to life events and sexuality (FEMALES) study. J Sex Med 2005;2:675-84.
24. Althof SE, Rubio-Aurioles E, Kingsberg S, Zeigler H, Wong DG, Burns P. Impact of tadalafil once daily in men with erectile dysfunction-including a report of the partners' evaluation. Urology 2010;75:1358-63.
25. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177:1401-7.
26. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008;180:1228-34.
27. Kaplan SA, Hatzichristou D. Open to debate. The motion: PDE5 inhibitors will have a significant role in the treatment of BPH. Eur Urol 2007;52:1523-7.
28. Seftel AD, Wilson SK, Knapp PM, Shin J, Wang WC, Ahuja S. The efficacy and safety of tadalafil in United States and Puerto Rican men with erectile dysfunction. J Urol 2004;172:652-7.